U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Beta-sitosterol is one of the main dietary phytosterols found in plants which have a similar skeleton as cholesterol. In human clinical trials, beta-sitosterol has been shown to have cholesterol-lowering effects and to relieve symptoms of benign prostatic hyperplasia. There has been a large amount of basic research conducted for potential applications of beta-sitosterol in a diverse range of conditions including cervical cancer, breast cancer, cystic fibrosis, and others. Beta-sitosterol is available over the counter as a natural health supplement and is marketed for a wide range of applications including headaches, tuberculosis, allergies, cancers, fibromyalgia, lupus, asthma, hair loss and many others.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P42574
Gene ID: 836.0
Gene Symbol: CASP3
Target Organism: Homo sapiens (Human)
Target ID: P17252
Gene ID: 5578.0
Gene Symbol: PRKCA
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The influence of beta-sitosterol on biliary cholesterol saturation and bile acid kinetics in man.
1978
Beta-sitosterols for benign prostatic hyperplasia.
2000
Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells.
2003 Mar-Apr
Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews.
2012 Nov
Effect of β-sitosterol on the expression of HPV E6 and p53 in cervical carcinoma cells.
2015
Patents

Sample Use Guides

In Vivo Use Guide
Over 6 to 8 weeks beta-sitosterol supplementation of 12 g/day resulted in an average of 11% decrease in serum cholesterol and a 12% decrease in biliary cholesterol saturation.
Route of Administration: Oral
Human cervical cancer cell lines, Caski and HeLa, were cultured in RPMI-1640 and supplemented with 10% foetal bovine serum and incubated at 37 deg-c in an atmosphere with 5% CO2. Cells were treated with 20 umol/L of beta-sitosterol for 48 hours and examined for changes by light microscopy, electron microscopy, and transmission electron microscopy. Changes in mRNA and protein expression were quantified using Real-Time qPCR and western blots. The treatment with beta-sitosterol reduced expression of PCNA, increased p53 mRNA, decreased the amount of HPV E6 transcripts. Cells treated with beta-sitosterol also exhibited loss of cell surface microvilli and increased electron density in the cell membrane.
Substance Class Mixture
Created
by admin
on Fri Dec 15 16:57:56 GMT 2023
Edited
by admin
on Fri Dec 15 16:57:56 GMT 2023
Record UNII
G7V636VTDY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SITOSTEROLS
WHO-DD  
Common Name English
Sitosterols [WHO-DD]
Common Name English
SITOSTEROL
Common Name English
Classification Tree Code System Code
DSLD 2794 (Number of products:1)
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
Code System Code Type Description
FDA UNII
G7V636VTDY
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
CHEBI
27693
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
EVMPD
SUB15255MIG
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
WIKIPEDIA
Sitosterol
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
ChEMBL
CHEMBL2108117
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
MESH
D012855
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
RXCUI
9808
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY RxNorm
CAS
12002-39-0
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
DRUG CENTRAL
2451
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID401025687
Created by admin on Fri Dec 15 16:57:56 GMT 2023 , Edited by admin on Fri Dec 15 16:57:56 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Definition References